Elevance Health, Inc. (ELV) earnings on July 15, 2026
More Elevance Health, Inc. earnings
Prior outlook: Optimistic Outcome: Missed
Elevance Health's stock fell sharply after its earnings report. The market was disappointed with the company's outlook update, pushing the price down significantly.
ELV price around the earnings
390.33
Change: -8.5%
2026-07-15, 20:00 UTC
Start of the measured window
End of the measured window
376.97
397.31
417.66
438.00
426.79
July 15, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Missed
- Thesis published
Very strong positive trend strength with recent analyst upgrades into earnings; strong past beat history.
Context analyzed before publication
- Trend
- Score jumped from 52.7 to 87.8 — sharp positive trajectory, strong upgrade trend strength.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.82
- Analysts covering the stock
- 21
- Average price target
- 436.52
- Lowest price target
- 331
- Highest price target
- 498
- Upside to price target
- 2.3%
- Quarterly earnings growth
- -19.2%
- Revenue growth
- 2.6%
- Forward EPS
- 29.32
- Trailing EPS
- 23.6
- Analyst moves in the last 60 days
- 0
- Strong buy: 2
- Buy: 12
- Hold: 8
- Sell: 0
- Strong sell: 0
- Strong buy
- 2
- Buy
- 12
- Hold
- 8
- Sell
- 0
- Strong sell
- 0
News and sentiment
Evidence
Sentiment
- Sentiment
- Neutral
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (8)
- TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $465 — Benzinga
- Truist Securities Maintains Buy on Elevance Health, Raises Price Target to $475 — Benzinga
- Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492 — Benzinga
- RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $439 — Benzinga
- Cantor Fitzgerald Maintains Overweight on Elevance Health, Raises Price Target to $450 — Benzinga
- Insurer Elevance Seeks Recalculated Medicare Star Rating in Lawsuit — Benzinga
- CNSide Diagnostics Strikes Deal With Elevance Health To Offer CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay, Effective May 1, 2026 — Benzinga
- Elevance Health Invests $640M In Affordable Housing Over The Past Five Years, Building On More Than $1B Invested Over Nearly Two Decades — Benzinga
Technicals
Evidence
- Average true range (ATR)
- 2.5%
- Distance to 52-week high
- +0.0%
- 14-day change (14d)
- +8.9%
- 30-day change (30d)
- +9.3%
- 30-day relative strength
- +9.3%
- Benchmark change (0d)
- +0.0%
- Nearest support
- 428.9
- Nearest resistance
- 431.8
- Volume accumulation ratio (14d / 46d)
- 0.93
Trends
Evidence
- Average earnings surprise
- +11.3%
- April 22, 2026: actual EPS 12.58 vs estimate 10.81 (surprise +16.4%)
- January 28, 2026: actual EPS 3.33 vs estimate 3.09 (surprise +7.7%)
- October 21, 2025: actual EPS 6.03 vs estimate 4.94 (surprise +22.0%)
- July 17, 2025: actual EPS 8.84 vs estimate 8.92 (surprise -0.9%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 3.2%
- 75th percentile move
- 5.9%
- 90th percentile move
- 8.3%
- Up / down moves
- 12 / 7
- Average up move
- +2.9%
- Average down move
- -6.4%
Monitoring and close
What Elevance Health, Inc. reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Missed
- Consolidated
- -8.5%
- Max favorable move (MFE)
- 2.6%
- Max adverse move (MAE)
- 11.9%